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Objectives/Hypothesis: To develop and character-
ize a new model of laryngeal inflammation by analyzing
the presence of neurogenic peptides and expression of
cyclooxygenases (COX) and cytokines in the mucosa.
Study Design: Laryngitis induced by nasogastric
intubation (NGI) was evaluated by histopathologic
changes of the mucosa, alterations in calcitonin gene re-
lated peptide (CGRP) and substance P (SP) neuropep-
tides in sensory fibers, and COX-1,2, and cytokine (inter-
leukin [IL]-1, IL-6, IL-10, tumor necrosis factor [TNF]-)
expression in the laryngeal mucosa.
Methods: Rats submitted to NGI for 1 to 5 weeks
were compared with controls. Laryngeal sections were
immunostained for stereologic analysis of SP and CGRP
fiber density and number of mucosal cells expressing
COX-2. Alterations in inflammatorymediators were eval-
uated by quantitative reverse-transcriptase polymerase
chain reaction.
Results: NGI induced metaplasia of the epithelium
and narrowing of the laryngeal lumen because of hyper-
trophy of laryngeal glandules and edema. An initial de-
crease in CGRP- and SP-immunoreactive fibers in the
laryngeal mucosa (1–3 wk) was reverted with time (5 wk).
COX-2 expression in mucosal cells increased progres-
sively, reaching a maximum level at 5 weeks, and was
observed in mononuclear immune cells, which is indica-
tive of a chronic inflammatory process. In regard to
mRNA expression levels of inflammatory mediators,
TNF- was increased during the 5 week NGI, and IL-10
decreased during the 5 weeks,whereas IL-1, IL-6, and
COX-2 increased in the first 1 to 2 weeks and returned to
baseline at 5 weeks.
Conclusions: This NGI model results in laryngeal
chronic inflammation without direct mechanical aggres-
sion of the mucosa and may contribute to the study of
future therapeutic approaches to this pathology.
Key Words: Laryngeal inflammation, neuropep-
tides, cyclooxygenase-2, cytokines, nasogastric intuba-
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Nasogastric intubation (NGI) is largely used in clin-
ical practice.1 However, several complications such as lar-
yngitis2 and increased mortality because of aspiration
pneumonia can be induced by this procedure. The exper-
imental studies determining the mechanisms of laryngeal
injury associated with nasogastric tubes are scarce.2 Neu-
rogenic mechanisms are implicated in many inflammatory
diseases, and three group of factors are involved: 1) hy-
drogen ions (H) and adenosine triphosphate released by
damaged tissue; 2) inflammatory mediators, including
prostaglandins (PGs) and pro-inflammatory cytokines
such as interleukin (IL)-1, IL-6, and tumor necrosis fac-
tor (TNF)-, and anti-inflammatory cytokines (IL-10); 3)
and neurogenic peptides substance P (SP) and calcitonin
gene related peptide (CGRP) present in the nerve fibers of
the mucosa.3 We previously demonstrated that neuropep-
tides SP and CGRP are present in the laryngeal sensory
fibers that reach the epithelium surface and project to the
respiratory lumen.4 Because these fibers are accessible to
direct stimulation, the rat laryngeal mucosa may consti-
tute a good experimental model for studying the activation
of primary afferents during the development of neurogenic
inflammation.4 SP and CGRP are important peptides in
laryngeal sensory reflexes of cough and bronchial-
pulmonary defense and can induce inflammatory re-
sponses in the respiratory tract.5 As concerns the larynx,
it is possible that these peptides can also induce laryngi-
tis, but to the best of our knowledge, there are no experi-
mental studies analyzing the expression of peptides and
ILs such as IL-1, IL-6, IL-10, and TNF- in laryngeal
inflammation.
From the Life and Health Sciences Research Institute (ICVS) (M.L.-R.,
A.V.-F., N.L., A.C., F.B., F.M., R.M.R., A.G.C., A.A.), School of Health Sciences,
University of Minho, Braga, Portugal; the Institute of Molecular Pathology
and Immunology (IPATIMUP) (F.M.), University of Oporto, Porto, Portugal;
and the Faculty of Medicine of Oporto (R.M.), Porto, Portugal.
Editor’sNote: ThisManuscriptwas accepted for publication June27, 2007.
This study was supported by Fundac¸a˜o para a Cie´ncia e Tecnologia
(FCT) Project No. POCTI/NSE/46399/2002, FEDER, and Fundac¸a˜o Cal-
ouste Gulbenkian Project No. 74551.
Send correspondence to Professor Armando Almeida, School of
Health Sciences University of Minho, Campus de Gualtar, 4710-057 Braga,
Portugal. E-mail: aalmeida@ecsaude.uminho.pt
DOI: 10.1097/MLG.0b013e3181492400
Laryngoscope 117: XX 2007 Lima-Rodrigues et al.: Characterization of a New Model of Laryngitis
1
Acute and chronic inflammation induce the expres-
sion of cyclooxygenase (COX)-2 and release of PGs from
arachidonic acid, which is cleaved from cell membrane
phospholipids of damaged tissue.3 PGs activate receptors
in fiber membranes, triggering the cyclic adenosine mono-
phosphate protein kinase A transduction pathway that
increases intracellular calcium and releases SP from in-
flamed peripheral nerves, which further activates fibers
by stimulating neurokin-1 receptors. CGRP receptors are
colocalized with PG receptors at thin nerve terminals, and
CGRP-receptor activation potentiates the effect of SP by
retarding its release. Pro-inflammatory cytokines (IL-1,
TNF-, and IL-6) produced after tissue damage induce
COX-2 synthesis and cells to release PGs.3 The expression
of COX-2 and COX-1 (constitutive) and their relation to
neurogenic peptides and cytokines in chronic laryngitis is
unknown. We designed an experimental rat model of NGI
to obtain chronic inflammation of the larynx in which we
evaluated potential changes in the 1) normal histology of
the mucosa, 2) SP- and CGRP-immunoreactivity in laryn-
geal sensory fibers, 3) COX-2 expression in inflammatory
cells of the lamina propria, and 4) COX-1, COX-2, IL-1,
IL-6, IL-10, and TNF- mRNA expression in the mucosa.
MATERIALS AND METHODS
Animals
This study was performed in 54 male rats weighing 350 to
450 g obtained from the Wistar Han colony of Charles Rivers
Company (Barcelona, Spain). Animals were lightly anesthetized
with inhaled isoflurane to allow swallowing reflex and were sub-
mitted to the NGI procedure. A 10 to 12 cm narrow-bore naso-
gastric aspiration tube used for NGI in premature newborns (cat.
No 533.04; Vigon Laboratoires Pharmaceutiques, Ecouen,
France) was inserted through the nasopharynx until it reached
the stomach. The external tip was sutured to the nasal lateral
cartilages. Animals recovered and returned to their cages, being
submitted to NGI for 1 (nimuno  6; nPCR  7), 2 (nimuno  6;
nPCR  6), 3 (nimuno  6), and 5 (nimuno  6; nPCR  6) weeks.
Twelve (nimuno  6; nPCR  6) nonintubated rats were used as
controls (CONT). At the end of the intubation period, animals for
immunohistochemical experiments were perfused under anesthe-
sia (isoflurane and 35% chloral hydrate intraperitoneally)
through the ascending aorta with 4% paraformaldehyde in
phosphate-buffered saline (PBS) 0.01 mol/L. After confirmation
that the NGI tube was still inserted in the stomach, the larynx
was removed and immersed in the same fixative followed by 30%
sucrose in 0.1 mol/L PBS overnight. Animals used for real-time
reverse-transcriptase polymerase chain reaction (RT-PCR) stud-
ies were anesthetized with isoflurane and sacrificed with 35%
chloral hydrate intraperitoneally. Larynxes were excised imme-
diately, macerated, immersed in 0.8 mL of TRIzol (Invitrogen,
Carlsbad, CA), and stored at –80°C. The experiments were car-
ried out in accordance with regulation of local authorities for
handling laboratory animals (Veterinary General Directive
Board, Ministry of Agriculture, Rural Development and Fishing)
and European Community Council Directive 86/609/EEC.
pHmetry
Measurements of pH were performed using a MI-414–4
cm pH combination microelectrode probe (Microelectrodes, Inc.,
Bedford, NH) attached to an Inolab pH Level 1 potentiometer
(Wissenschaftlich Technische Werksta¨tten, Weillem, Germany).
First, the pharyngeal pH and then the esophageal pH were re-
corded for each animal immediately before sacrifice (5 s for each
pH measurement).
Histology and Immunocytochemistry
Laryngeal coronal frozen sections (20 m) obtained with a
cryostat were processed for immunohistochemistry. Alternate
sections were incubated overnight at room temperature with
rabbit antiCGRP (1:6,000; Bachem, Sao Carlos, CA) or rabbit
antiSP (1:6,000; Bachem) antibodies in PBS with 0.3% triton
X-100 (PBST). After rinsing in PBST, the sections were then
incubated with biotinylated goat anti-rabbit (1:200; Vector Lab-
oratories Inc, Burlingame, CA) in PBST for 1 hour, washed in
PBST, and then incubated with avidin-biotin complex (1:200;
Vector Laboratories Inc, Burlingame, CA) in PBS for 1 hour. After
rinsing in PBS and 0.1 mol/L tris-HCl buffer (pH 7.4), the
TABLE I.




-Actin Forward primer 5 – GATTTGGCACCACACTTTCTACA – 3 NM_031144
Reverse primer 5 – ATCTGGGTCATCTTTTCACGGTTGG – 3
IL-1 Forward primer 5 – GAAACAGCAATGGTCGGGAC – 3 M98820
Reverse primer 5 – GAGACCTGACTTGGCAGAGG – 3
TNF- Forward primer 5 – CCAACAAGGAGGAGAAGTTC – 3 NM_012675
Reverse primer 5 – CCTGGTGGTTTGCTACGAC – 3
IL-6 Forward primer 5 – CAAGAGACTTCCAGCCAG – 3 NM_012589
Reverse primer 5 – CTCCGACTTGTGAAGTGGT – 3
IL-10 Forward primer 5 – GCCAAGCCTTGTCAGAAATGA – 3 NM_012854
Reverse primer 5 – TTTCTGGGCCATGGTTCTCT – 3
COX-1 Forward primer 5 – GGCGTTGCTCATCCATCTACTC – 3 S67721
Reverse primer 5 – AGCATCTGTGAGCAGTACCGG – 3
COX-2 Forward primer 5 – TTTGTTGAGTCATTCACCAGACAGAT – 3 S67722
Reverse primer 5 – ACGATGTGTAAGGTTTCAGGGAGAAG – 3
IL  interleukin; TNF  tumor necrosis factor; COX  cyclooxygenase.
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antigen-antibody reaction was visualized with diaminobenzidine
(DAB, Sigma, St. Louis, MO).
COX-2 immunohistochemistry was carried out according to
the streptavidin-biotin-peroxidase complex technique (Ultravi-
sion Detection System Antipolyvalent, HRP, Lab Vision Corpora-
tion, Fremont, CA) using a primary antibody raised against
COX-2 protein (1:400; rabbit monoclonal antibody, clone SP21;
Neomarkers, Fremont, CA). Slides were sequentially washed in
PBS/0.02% Tween 20 and incubated with 3% H2O2 in methanol
for 10 minutes. This was followed by incubation with blocking
solution for 10 minutes and the primary antibody solution for 2
hours at room temperature. Sections were then sequentially
washed in PBS/0.02% Tween 20 and incubated with biotinylated
goat antipolyvalent antibody for 10 minutes and streptavidin
peroxidase for 10 minutes. DAB was used as chromogen. Slides
were counterstained with Mayer hematoxylin (Merck, Darm-
stadt, Germany). Negative controls were performed by omission
of the primary antibody. A colon carcinoma sample was used as
positive control.
Stereologic Procedures
Sections were analyzed with an Axioskop 2 plus light mi-
croscope (Carl Zeiss, Go¨ttingen, Germany), and images of laryn-
geal histologic data were taken using an Axiocam HRC camera
and AxioVision 3.1 software (Carl Zeiss). Cell and fiber numbers
were estimated using the optical fractionator method.6 This con-
sists of virtual 3–dimensional-box (150  150  30 m), equally
spaced grids that were superimposed on every eighth coronal
laryngeal section after drawing the limits of the area under study
in the laryngeal mucosa. The number of COX-2 immunoreactive
cells and SP- and CGRP-immunoreactive fibers that crossed the
gridlines in every randomized site (chosen by the software) was
counted according to well-defined stereologic rules. The estimated
numbers were calculated from the ratio between the total number
of counted cells and fibers crossing the grid site and the number
of grid sites per area. The coefficients of error were automatically
computed by the software according to the formulas of Gundersen
for cell numbers.6
mRNA Extraction and Real-Time RT-PCR
Total mRNA in the larynx was extracted by adding 160 L
CHCl3 followed by centrifugation at 13,000 rpm for 15 minutes at
4°C. The supernatant was carefully collected, and total mRNA
was precipitated using isopropanol (2-propanol) followed by cen-
trifugation at 13,000 rpm for 15 minutes at 4°C. The mRNA pellet
was washed using 70% ethanol recentrifuged at 9,000 rpm for 5
minutes at 4°C, dried, and suspended with 50 L of DNAse/
RNAse free distilled water (Gibco, Carlsbad, CA). Quantification
of total mRNA was performed by spectrophotometry (NanoDrop,
NanoDrop Technologies, Inc., Wilmington, NC). Samples of total
mRNA with the same concentration (2 ng/10 L) were then re-
verse transcribed in a thermocyclator My Cycler Thermal Cycler
(Bio-Rad, Hercules, CA) using a Superscript Kit II (Invitrogen)
and Oligo dT (Invitrogen), according to the manufacturer’s
Fig. 1. Changes in histology and cyclo-
oxygenase (COX)-2 expression of the la-
ryngeal mucosa after no nasogastric in-
tubation (NGI) (A, D, G) and 2 (B, E, H)
and 5 (C, F, I) weeks of induction of the
NGI model. A large increase of the glan-
dular tissue was observed with increas-
ing periods of laryngeal inflammation (A
to C; arrows, D to F), with a consequent
decrease in the laryngeal lumen (A to C).
This was accompanied by large prolifer-
ation of mononuclear immune cells im-
munoreactive to COX-2 (arrows, G to I).
L  laryngeal lumen. Magnification
bar  100 m.
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instructions. The cDNA was then subjected to real-time RT-PCR
reactions for quantification of mRNA levels of -Actin, IL-1,
TNF-, IL-6, IL-10, COX-1, and COX-2, using the LightCycler
(Roche, Basel, Switzerland), and an SYBR Green PCR Master
Mix (QIAGEN GmbH, Hilden, Germany) was used according to
the manufacturer instructions. Primer sequences used to amplify
various cDNAs are shown in Table I. A typical real-time RT-PCR
protocol was performed under the following conditions: 15 min-
utes at 95°C, followed by 40 cycles (94°C denaturing for 15 s; 58°C
annealing for 20 s; 72°C extension for 15 s), melting at 60°C until
95°C for 90 seconds, and finally cooling to 35°C. The specificity of
the SYBR Green assays was confirmed by melting point analysis.
Gene expression of the housekeeping gene -Actin was used for
normalization of the results.
Data Analysis
Results were analyzed using Graph Pad Prism version
4.00 for Windows (Graph Pad Software, San Diego, CA). Means
were compared using one-way analysis of variance (ANOVA)
statistical evaluation followed by Tukey honestly significant
difference post hoc test, and differences were considered to be
significant at P  .05.
RESULTS
Histological and pHmetry Changes Induced
by NGI
NGI induces a visible reduction of the laryngeal lu-
men (Fig. 1A–C), a consequence of a progressively increas-
ing hyperplasia and hypertrophy of the glandular tissue
(Fig. 1D–F). After 5 weeks of NGI, some areas of the
epithelium showed a replacement of the differentiated
pseudostratified respiratory epithelium of the larynx (Fig.
2A) by a squamous-stratified epithelium (metaplasia) and
edema in the connective tissue (Fig. 2B). In addition, a
large proliferation of plasmocytes and a few lymphocytes
were present in the connective tissue of the mucosa
(chronic inflammation) (Fig. 2C and D).
NGI resulted in significant changes in the pH re-
corded at the pharynx and esophagus (ANOVA, P  .001).
Control rats showed a different pH between the pharyn-
geal and esophageal mucosa (CONTP CONTE, P .001)
(Fig. 3). No differences were observed after 1 week of NGI
(NGIP1w  NGIE1w, P  .05) because of a significant
decrease in pharyngeal pH (NGIP1w  CONTP, P  .01)
(Fig. 3). After 2 weeks NGI, pH differences between
Fig. 2. Histologic changes in the con-
nective tissue of the laryngeal mucosa
induced by the nasogastric intubation
(NGI) experimental model. Note replace-
ment of typical ciliated pseudostratified
respiratory epithelium (arrow, A) by an-
other differentiated squamous stratified
(nonkeratinized) epithelium (metaplasia)
after 5 weeks of NGI (arrow, B). In addi-
tion, presence of chronic inflammation
signs is evident, namely edema (aster-
isks, B) and large proliferation of mono-
nuclear immune cells in the lamina pro-
pria (arrows, C), including plasmocytes
(arrows, D). Magnification bar  100 m.
Fig. 3. Changes in the pH of the pharyngeal and esophageal mu-
cosa measured at the end of the experimental period. Values for
pharyngeal pH are placed at the left of the dashed line, whereas
esophageal pH are recorded at the right. Control P and 1- to 5-week
(W) nasogastric intubation (NGI) P  pharyngeal pH values for
control and NGI animals; control E and 1 to 5 W NGI E  esophagic
pH values for control and NGI animals. Only significant differences
between pH values obtained in the same location are recorded in
the graph. *P  .05, **P  .01, and ***P  .001.
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mucosae were again significant (NGIP2w  NGIE2w, P 
.001), a trend still observed after 5 weeks NGI (although
not reaching significance) (Fig. 3). No differences were
observed in the esophageal pH along the NGI period.
Changes in Laryngeal Peripheral
Sensory Enervation
CGRP-immunoreactive fibers were present in the ep-
ithelium and connective tissue of the lamina propria of the
laryngeal mucosa (Figs. 4A and 5A–C). Laryngeal immu-
nostaining of SP depicted an intraepithelial nerve plexus
with an overall location similar to that of CGRP fibers but
with a lower density of fibers both in control and intubated
animals (Figs. 4B and 5D–F). NGI induced changes in the
expression of neurogenic peptides (ANOVA, P  .05), with
the number of CGRP-and SP-immunoreactive fibers de-
creasing already during the first week of NGI (CGRP:
NGI1w  CONT, P  .01) and remaining decreased at the
third week (CGRP: NGI3w  CONT, P  .001; SP:
NGI3w  CONT, P  .001) (Figs. 4 and 5). Between 3 and
5 weeks, there was an increase in the number of fibers
immunoreactive to CGRP (NGI3–5w CONT, P .05) and
SP (NGI3–5w  CONT, P  .01) (Fig. 5), a recovery that
reached control values in SP fiber density (NGI5w 
CONT, P  .05) (Fig. 4B) and was near control values in
terms of CGRP fiber density (NGI5w  CONT, P  .05)
(Fig. 4A).
COX-2 Expression in Laryngeal Mucosa
The NGI model also induced changes in the expres-
sion of COX-2 in the laryngeal mucosa (ANOVA, P  .05).
The number of cells expressing COX-2 enzyme in the
laryngeal mucosa was higher after 2 weeks of NGI and
increased significantly until the fifth week (NGI5w 
CONT, P  .05) (Fig. 6). This was caused by a progressive
increase in the number of mononuclear inflammatory cells
expressing COX-2 in the lamina propria (Fig. 1G–I), lym-
phocytes, and plasma cells (Fig. 2), which is characteristic
of chronic inflammation. However, in regard to the rela-
tive expression of COX-2 mRNA levels in the laryngeal
mucosa (ANOVA, P  .01), the progressive increase until
the second week (NGI2w  CONT, P  .01) was followed
by a reduction to control values at 5 weeks (NGI2w 
NGI5w, P  .05) (Fig. 7A). On the contrary, no changes
were observed in mRNA laryngeal levels of COX-1 consti-
tutive enzyme (ANOVA, P .27) (Fig. 7B). Thus, the ratio
COX-2/COX-1 mRNA expression was changed after NGI
(ANOVA, P  .05), with an increase until the second week
(NGI2w  CONT, P  .05), followed by a return to control
values at the end of the experimental period (Fig. 7C).
Laryngeal Levels of Pro-Inflammatory and Anti-
Inflammatory Cytokines
The NGI model induced drastic changes of inflamma-
tory mediators. The relative expression of IL-1 mRNA
changed along the experimental period (ANOVA, P 
.0001), increasing continuously after 1 week (NGI1w 
CONT, P  .01) and 2 weeks (NGI2w  CONT, P  .001;
NGI1w  NGI2w, P  .01) but returning to control values
at 5 weeks NGI (NGI2–5w, P  .001) (Fig. 8A). NGI af-
fected the level of expression of TNF- mRNA (ANOVA,
P  .001), which increased after 1 week (NGI1w  CONT,
P  .001) and maintained a significant increased expres-
sion until the end of the experiment (NGI2w  CONT, P 
.01; NGI5w  CONT, P  .01) (Fig. 8B). IL-6 mRNA
changed significantly (ANOVA, P  .0001) in the laryn-
geal mucosa, showing an increase 1 week after NGI
(NGI1w  CONT, P  .001) and then a progressive de-
crease until control values at 5 weeks (NGI2w  CONT,
P  .01; NGI1–5w, P  .001; NGI2–5w, P  .05) (Fig. 8C).
Changes in mRNA levels of the anti-inflammatory cyto-
kine IL-10 (ANOVA, P  .001) showed a strong decrease 1
week after NGI (NGI1w  CONT, P  .001), which was
still observed 5 weeks later (NGI2W  CONT, P  .001;
NGI5w  CONT, P  .001) (Fig. 8D).
As concerns the analysis of the ratio between pro-
inflammatory and anti-inflammatory cytokines, pro-
inflammatory changes prevailed over anti-inflammatory
Fig. 4. Density of calcitonin gene-related peptide (CGRP)- (A) and
substance P (SP)- (B) immunoreactive fibers in the laryngeal mu-
cosa of animals without nasogastric tube (control group) and after
different periods of nasogastric intubation (NGI). Note the significant
decrease in the presence of these neurogenic peptides in laryngeal
sensory fibers until the third week of NGI and the total (SP) or partial
(CGRP) recovery observed at the end of the experimental period (5
wk). Asterisks over each week are comparisons with control values,
whereas asterisks over each bar represent comparisons between val-
ues of groups submitted to NGI. *P  .05, **P  .01, and ***P  .001.
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alterations. Accordingly, the ratio between IL-1 and
IL-10 mRNA expression changed with time after NGI
(ANOVA, P  .0001), with a progressive increase until
the second week (NGI1w  CONT, P  .05; NGI2w 
CONT, P  .001), followed by a return to control values
(Fig. 8E). Interestingly, no changes were obtained for
the ratio between TNF- and IL-10 (Fig. 8F).
DISCUSSION
In the present study, we developed an NGI experi-
mental model to induce laryngeal inflammation without
direct mechanical injury to preserve the epithelium and
lamina propria of the larynx. For model characterization,
we showed that CGRP and SP present in nociceptive pe-
ripheral fibers decreased initially and then returned to
control values. The inducible COX-2 enzyme shows the
inverse pattern, increasing initially and then returning to
baseline. However, the number of cells expressing COX-2
increased in inflammatory cells with increasing periods of
NGI. Finally, IL-1 and IL-6 cytokines showed a pattern
of mRNA expression along the 5 week NGI that was sim-
ilar to COX-2 and inverse to CGRP and SP, whereas
TNF- was always increased and levels of IL-10 were
always decreased along NGI.
Neurogenic inflammation is a well-defined process by
which inflammation is triggered by the nervous system.
As a pathway distinct from antigen-driven immune-
mediated inflammation, it may play a key role in the
understanding of a broad class of environmental health
problems. It is a common pathway for disease in many
organs and systems,7–9 and a growing amount of evidence
implicates the involvement of neurogenic etiology in dis-
orders such as asthma, rhinitis, contact dermatitis, mi-
graine headache, and rheumatoid arthritis.10,11 In the re-
spiratory tract, recent progresses in understanding the
morphology of nerve fibers showed that intraepithelial
nociceptors containing SP and CGRP neurogenic peptides
project into the lumen of the larynx and can be directly
stimulated by irritant substances.4 The role of primary
sensory neurons in arteriolar vasodilatation, increased
vascular permeability, and leukocyte infiltration is medi-
ated by peripheral release of peptides such as SP and
CGRP from nerve terminals of depolarized peripheral
nerve fibers.12 SP binds to the neurokinin-1 receptor on
target cells such as immune cells and vascular endothelial
cells11,13 and is the main mediator of vascular permeabil-
ity and leukocyte infiltration, whereas CGRP is the prime
mediator of neurogenic vasodilatation.8,9 Moreover, SP
Fig. 5. Photomicrographs of calcitonin
gene-related peptide (CGRP)- (A to C)
and substance P (SP)- (D to F) immuno-
reactive fibers in the laryngeal epithe-
lium of animals without nasogastric tube
(controls, A and D) and after 3 (B and E)
and 5 (C and F) weeks of nasogastric
intubation (NGI). Note the strong de-
crease in CGRP and SP immunoreactive
fibers (arrows) from nonintubation (A
and D) to 3 weeks of laryngeal inflam-
mation (B and E) and the recovery in the
density of nociceptive primary afferent
fibers containing CGRP and SP after 5
weeks of NGI (C and F). Magnification
bar  50 m.
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can increase production and release of PGE214 and release
of IL-1.15 Thus, the here observed initial decrease in
CGRP and SP content in laryngeal sensory fibers (first 3
wk) probably resulted from the release of these peptides
from mucosal nociceptors and induction of neurogenic in-
flammation. This is supported by the fact that PGE2, one
important member of the E series of PGs, facilitates the
release of neurogenic peptides SP and CGRP from pri-
mary sensory neurons.16
In regard to the partial recovery of CGRP and SP
innervation between the third and fifth week of NGI, this
may reflect a progressive refilling of laryngeal nociceptors
with these peptides after their synthesis in perikarya of
primary sensory neurons. Accordingly, the decreased ex-
pression of COX-2 mRNA to control values may account
for a decrease in the release of SP and CGRP from primary
afferents, which results in an increase of SP and CGRP
immunoreactivity in peripheral fibers after 5 weeks NGI.
On the other hand, there was an apparent disagreement
between the continuous increase of COX-2 positive cells
present in the laryngeal mucosa along the 5 weeks of NGI
and the peak of COX-2 mRNA expression after 2 weeks
NGI followed by a return to control values at 5 weeks. The
progressive increase of the number of COX-2 immunore-
active cells until the fifth week of laryngeal inflammation
should reflect not mRNA expression for de novo produc-
tion of the enzyme but rather the recruitment of immune
cells containing COX-2 to the inflamed larynx. Interest-
ingly, prolonged over-production of PGs by COX-2 can
increase SP and CGRP immunoreactivities in primary
sensory neurons.17 Thus, the increased number of COX-2
immunoreactive cells in the laryngeal mucosa after 5
weeks (but not 3 wk) of laryngeal inflammation may also
contribute to the recovery of laryngeal SP and CGRP
content after 5 weeks of NGI.
In the present study, the inflammation observed with
NGI may have two origins. First is the presence of the
nasogastric tube passing through the pharynx to the
esophagus, which can indirectly have a mechanical effect
Fig. 6. Density of cyclooxygenase (COX)-2 immunoreactive cells in
the laryngeal mucosa of animals without nasogastric tube and after
2 and 5 weeks of nasogastric intubation (NGI). Note the continuous
increase in COX-2 containing cells in the laryngeal mucosa, which
reaches significance at 5 weeks. *P  .05, **P  .01, and ***P 
.001.
Fig. 7. Relative expression of cyclooxygenase (COX)-2 and COX-1
mRNA levels obtained by reverse-transcription polymerase chain
reaction in the laryngeal mucosa of animals with or without induc-
tion of the nasogastric intubation (NGI) model. Note the rise of
COX-2 mRNA expression until the second week and the return to
basal values at the end of the experimental period (A). On the
contrary, no changes were observed on the levels of the constitutive
COX-1 enzyme (B). In regard to COX-2/COX-1 ratio of mRNA ex-
pression, the sequence of alterations was similar to that described
for COX-2 (C). *P  .05, **P  .01, and ***P  .001.
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on the mucosa of the adjacent larynx. Second, the presence
of acid from gastroesophagic reflux can directly activate
nociceptors because H ions have receptors in the cell
membrane of these fibers.7 Accordingly, protons can in-
duce CGRP release after activation of their receptors,16 as
observed here during the first weeks of NGI. The activa-
tion of nociceptors by noxious stimulation induces release
of SP and CGRP, which increase blood vessel permeability
and plasma extravasation.7 Resident mast cells and other
immune cells attracted to the inflamed laryngeal mucosa
release cytokines and contribute to recruitment of more
leukocytes and macrophages that release PGs and addi-
tional cytokines.18 Cytokines IL-1, IL-6, and TNF- are
well-known mediators of inflammation18 because they
cause PG release after production of arachidonic acid.
Thus, cytokines form a link between tissue damage and
inflammatory responses.7 Binding of IL-1 to receptors on
cell membrane initiates signaling cascades that up-
regulate transcription of genes such as COX-2, TNF-,
and IL-6. Moreover, IL-1 facilitates release of CGRP
from nociceptors, probably by direct sensitization of noci-
ceptors, whereas TNF- sensitizes and induces ectopic
activity in these primary afferent fibers.18 These data
strongly support the here observed matching opposite evo-
lution of mRNA expression levels of IL-1, IL-6, and
COX-2 when compared with neurogenic peptides CGRP
and SP present in nociceptive laryngeal fibers (decreasing
during the first weeks and returning to control values at 5
wk). In regard to pro-inflammatory TNF- and anti-
inflammatory IL-10, their mRNA levels of expression in
the laryngeal mucosa was, respectively, increased or de-
creased along the 5 weeks of NGI. This matching opposite
evolution between the two cytokines is supported by other
studies showing a similar close interaction.18
Although many functions have been suggested for
COX-2, and the anti-inflammatory COX-2 inhibitors are
known to have less aerodigestive adverse side effects,16
the precise distribution and role of this enzyme is still
unclear, and few studies on its role in chronic inflamma-
tion have been performed in the respiratory tract. In our
study, the large increase in COX–2-immunoreactive in-
flammatory cells in the laryngeal mucosa after chronic
NGI was noticed in mononuclear immune cells. This is
clearly suggestive of the involvement of COX-2 in this
form of laryngitis, and the location in mononuclear cells
demonstrates a chronic inflammatory process. Selective
COX-2 nonsteroidal anti-inflammatory drugs (NSAIDs)
have less side effects than traditional (both antiCOX-1
Fig. 8. Relative expression of mRNA
levels obtained for pro-inflammatory
and anti-inflammatory cytokines in
the laryngeal mucosa of animals with
or without induction of the laryngitis
inflammatory model. Note the differ-
ent evolution of expression of inter-
leukin (IL)-1 (A), tumor necrosis fac-
tor (TNF)- (B), IL-6 (C), and IL-10 (D).
Although IL-1 and IL-6 showed a
peak of expression (1–2 wk nasogas-
tric intubation [NGI]) followed by a
return to baseline values (5 wk NGI, A
and C), TNF- was increased along
the entire period of NGI (B), and IL-10
was decreased along the 5 weeks of
NGI (D). In regard to the IL-1/IL-10
(E) and TNF-/IL-10 (F) ratios of
mRNA expression comparing pro-
and anti-inflammatory cytokines, the
sequence of alterations on the former
was similar to that described for Il-
1, whereas the latter showed no al-
terations during experimental period.
*P  .05, **P  .01, and ***P  .001.
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and COX-2) NSAIDs on the digestive and respiratory sys-
tems because protective PGs do not decrease, whereas
pro-inflammatory leukotrienes do not increase.16 Accord-
ingly, COX-1 inhibitors such as ibuprofen are effective in
acute respiratory diseases but not in chronic pathologies
because of their adverse side effects. The present model
can be used in the future for evaluating the potential
therapeutic value of selective COX-2 drugs in the treat-
ment of chronic laryngitis.
CONCLUSIONS
A new animal model of chronic laryngitis was de-
scribed, which results from NGI, a common technical pro-
cedure used in clinical practice. The resulting laryngitis
develops an inflammatory process that presents a neuro-
genic component. COX-2 is also implicated in the inflam-
matory mechanism because its expression increases with
time of intubation in mononuclear immune cells. Different
patterns of mRNA expression of pro-inflammatory and
anti-inflammatory mediators further characterized the in-
flammatory changes along time. This experimental NGI
model of chronic laryngitis may be useful for future stud-
ies 1) in analyzing the molecular development of chronic
inflammatory syndromes of the larynx, 2) in determining
the clinical long-term consequences for chronic NGI pa-
tients, and 3) in evaluating the effect of new therapeutic
approaches for clinical treatment of prolonged laryngitis.
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